<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01027286</url>
  </required_header>
  <id_info>
    <org_study_id>09-548</org_study_id>
    <nct_id>NCT01027286</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of Vitagel for Reduction in Blood Loss and Pain Following Unilateral Total Knee Arthroplasty</brief_title>
  <official_title>Prospective Evaluation of Vitagel for Reduction in Blood Loss and Pain Following Unilateral Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orthovita d/b/a Stryker</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitagel® is an FDA approved class III medical device. It is a surgical hemostat, which has
      been shown to control bleeding during orthopaedic, cardiac, hepatic, and general surgical
      procedures. The product is a thrombin/collagen suspension which works in combination with the
      patient's own plasma to form a fibrin/collagen clot.

      The present prospective, randomized controlled trial is designed to evaluate the efficacy of
      Vitagel® for reducing blood loss and pain in patients managed with unilateral total knee
      arthroplasty (TKA). It is hypothesized that the use of Vitagel® may lead to less blood filled
      knees, and thus to a greater improvement in postoperative pain scores when compared to the
      control group. The two arms of the study will include:

        1. experimental group in which Vitagel® is used unilateral TKA

        2. control group representing our current standard of care (no Vitagel®)

      A comparison of the functional and clinical results between these two groups will be
      conducted using several outcome measures including the KOOS, SF-12 version2 and pain scores
      through the previously IRB approved OrthoMidas registry. The primary variable of interest is
      blood loss, based on hemoglobin drop during the postoperative hospital stay. Of secondary
      interest will be; 1) pain levels in the PACU, 2) pain scores for all postoperative days, 3)
      average pain for the entire hospital stay, 4) length of stay, 5) patient satisfaction at
      discharge, 4 weeks postoperative, and 12 weeks postoperative, and 6) functional scores at 4
      and 12 weeks postoperative.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-center, randomized, double-blinded, clinical trial involving
      three orthopaedic surgeons who perform total knee replacement. The proposed study is optimal
      for obtaining clinical and functional comparisons between TKA surgical procedures utilizing
      conventional practices (control) and TKA utilizing Vitagel®, a surgical hemostat used to
      control bleeding and facilitate healing. The study will include patients that are receiving a
      unilateral primary TKA.

      Fifty cases will be assigned to each arm of the study (total 100 cases). This sample size was
      estimated using an alpha of 0.05 (conventional for all studies) and a beta of 0.80
      (recommended for superiority studies). The standard deviation is based on a study conducted
      by the PI at the Cleveland Clinic in an IRB approved retrospective project in 2007, and will
      provide in excess of 80 percent statistical power in detecting less than a 100 ml difference
      in blood loss between the two groups.

      The study will be conducted at the Cleveland Clinic (Cleveland, OH). The patients will not be
      informed of their treatment assignment, and the research investigator making observations and
      recording the data postoperatively will also be blinded to their treatment assignment. The
      placement of patients into treatment arms will be based on random drawing of sealed
      envelopes. An assessment of blinding will be conducted at the conclusion of the study by
      asking patients what treatment they think that they received.

      Data will be collected at four timepoints, including preoperatively, during the hospital
      stay, 4 weeks postoperatively, and 12 weeks postoperatively. Preoperative data collected will
      include baseline SF-12, KOOS, hemoglobin and hematocrit levels, and pain scores. Data
      collected in the hospital will include hemoglobin and hematocrit levels, pain scores,
      narcotics usage, length of stay, and patient satisfaction at discharge. The SF-12, KOOS, pain
      scores, and patient satisfaction will be collected utilizing the 4 week (±2 weeks) standard
      of care postoperative visit. Patients are not always seen at the 12 week (±4 weeks)
      postoperative timepoint as standard of care. To collect these data, patients will be mailed
      the SF-12, KOOS, pain scores, patient satisfaction, and blinding assessment questionnaires.
      Patients not responding to the initial mailer will be contacted by phone and sent a second
      packet of questionnaires.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Managed With Blood Transfusion</measure>
    <time_frame>daily during hospital stay (an expected average of 4 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Calculated Hospital Blood Loss</measure>
    <time_frame>daily during hospital stay (an expected average of 4 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperative &amp; Postoperative Hemoglobin Values</measure>
    <time_frame>within 30 days before surgery (preop), daily during hospital stay (an expected average of 4 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Narcotic Usage (Morphine-equivalent mg)</measure>
    <time_frame>daily during hospital stay (an expected average of 4 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>day of hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score Scale</measure>
    <time_frame>within 30 days before surgery (preop), 4 weeks after surgery, 12 weeks after surgery</time_frame>
    <description>A single scoring system used to evaluate overall pain on a scale of integers 0 to 10, with 0 representing &quot;no pain&quot; and 10 representing &quot;unbearable pain.&quot; Thus, in this context, lower values represent better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee Injury and Osteoarthritis Outcome Score (KOOS)</measure>
    <time_frame>within 30 days before surgery (preop), 4 weeks after surgery, 12 weeks after surgery</time_frame>
    <description>A scoring system used to evaluate the patient's opinion about his/her knee and associated problems. Subscales include 1) pain, 2) other symptoms, 3) function in daily living (ADL), 4) function in sport and recreation (Sport/Rec), and 5) knee related quality of life (QOL). Standardized answer options are given (5 Likert boxes) and each question is assigned a score from 0 to 4. A normalized score between 0 to 100 is calculated for each subscale. Subscale scores are generally not combined; rather, they are reported separated. Higher values represent better outcomes (i.e., less extreme symptoms).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Arthritis</condition>
  <arm_group>
    <arm_group_label>Vitagel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No Vitagel used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vitagel</intervention_name>
    <description>Vitagel applied just prior to closure during primary total knee arthroplasty</description>
    <arm_group_label>Vitagel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 - 85 years

          -  Sex: Both male and female will be included. The male-to-female ratio will depend upon
             the patient population.

          -  Stable Health: At the time of surgery based on physical examination and medical
             history.

          -  Patient exhibited preoperative radiographic evidence of joint degeneration consistent
             with TKA that could not have been treated in non-operative fashion.

          -  Patient had severe knee pain and disability due to degenerative joint disease.

          -  Patient or patient's legal representative has signed the Informed Consent form. The
             patient is capable of making informed decisions regarding his/her healthcare.

        Exclusion Criteria:

          -  Patients with history of liver disease. Patients with liver dysfunction from cirrhosis
             or hepatitis may have impaired production of factors in the clotting cascade which may
             make these individuals more prone to bleed, especially with the use of anticoagulants.
             For this reason, these patients will also be excluded from this study if a baseline
             INR if greater than 1.3.

          -  Patients allergic to materials of bovine origin.

          -  Patients predonating autologous blood.

          -  Patients with a preoperative platelet count of less than 100,000.

          -  Patients undergoing bilateral or revision surgery.

          -  Evidence of bleeding or metabolic - based hemolytic disorder (hemophilia or
             anticoagulation use), or hypercoaguable disorder.

          -  Previous history of infection in the affected joint.

          -  Peripheral vascular disease.

          -  Patient was a poor compliance risk - treated for ethanol or drug abuse, physical or
             mental handicap, etc.

          -  Patients with a previous history of venous thromboembolism, or other reason for
             requiring anticoagulation other than ASA 325 mg po BID and mechanical compression.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wael K Barsoum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bloomfield MR, Klika AK, Molloy RM, Froimson MI, Krebs VE, Barsoum WK. Prospective randomized evaluation of a collagen/thrombin and autologous platelet hemostatic agent during total knee arthroplasty. J Arthroplasty. 2012 May;27(5):695-702. doi: 10.1016/j.arth.2011.09.014. Epub 2011 Oct 27.</citation>
    <PMID>22035976</PMID>
  </results_reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2009</study_first_submitted>
  <study_first_submitted_qc>December 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2009</study_first_posted>
  <results_first_submitted>August 30, 2012</results_first_submitted>
  <results_first_submitted_qc>October 30, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 29, 2012</results_first_posted>
  <last_update_submitted>October 30, 2012</last_update_submitted>
  <last_update_submitted_qc>October 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vitagel</title>
          <description>Vitagel [Orthovita Inc., Malvern, PA], a collagen/thrombin and autologous platelet hemostatic agent, is applied just prior to surgical closure during primary total knee arthroplasty</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>No Vitagel used during primary total knee arthroplasty</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Preoperative</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Day of Surgery</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>4 Week Postoperative</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>12 Week Postoperative</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unable to Obtain Required Blood Volume</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitagel</title>
          <description>Vitagel [Orthovita Inc., Malvern, PA], a collagen/thrombin and autologous platelet hemostatic agent, is applied just prior to surgical closure during primary total knee arthroplasty</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>No Vitagel used during primary total knee arthroplasty</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.3" spread="8.2"/>
                    <measurement group_id="B2" value="62.4" spread="8.8"/>
                    <measurement group_id="B3" value="64.0" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Total Calculated Hospital Blood Loss</title>
        <time_frame>daily during hospital stay (an expected average of 4 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitagel</title>
            <description>Vitagel [Orthovita Inc., Malvern, PA], a collagen/thrombin and autologous platelet hemostatic agent, is applied just prior to surgical closure during primary total knee arthroplasty</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No Vitagel used during primary total knee arthroplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Total Calculated Hospital Blood Loss</title>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1577" spread="541"/>
                    <measurement group_id="O2" value="1620" spread="565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Managed With Blood Transfusion</title>
        <time_frame>daily during hospital stay (an expected average of 4 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitagel</title>
            <description>Vitagel [Orthovita Inc., Malvern, PA], a collagen/thrombin and autologous platelet hemostatic agent, is applied just prior to surgical closure during primary total knee arthroplasty</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No Vitagel used during primary total knee arthroplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Managed With Blood Transfusion</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preoperative &amp; Postoperative Hemoglobin Values</title>
        <time_frame>within 30 days before surgery (preop), daily during hospital stay (an expected average of 4 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitagel</title>
            <description>Vitagel [Orthovita Inc., Malvern, PA], a collagen/thrombin and autologous platelet hemostatic agent, is applied just prior to surgical closure during primary total knee arthroplasty</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No Vitagel used during primary total knee arthroplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Preoperative &amp; Postoperative Hemoglobin Values</title>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Preoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="1.3"/>
                    <measurement group_id="O2" value="13.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Anesthesia Care Unit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="1.3"/>
                    <measurement group_id="O2" value="11.8" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="1.2"/>
                    <measurement group_id="O2" value="10.4" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="1.2"/>
                    <measurement group_id="O2" value="9.7" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="1.3"/>
                    <measurement group_id="O2" value="9.4" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="1.0"/>
                    <measurement group_id="O2" value="8.8" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Narcotic Usage (Morphine-equivalent mg)</title>
        <time_frame>daily during hospital stay (an expected average of 4 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitagel</title>
            <description>Vitagel [Orthovita Inc., Malvern, PA], a collagen/thrombin and autologous platelet hemostatic agent, is applied just prior to surgical closure during primary total knee arthroplasty</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No Vitagel used during primary total knee arthroplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Narcotic Usage (Morphine-equivalent mg)</title>
          <units>morphine-equivalent mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Postoperative Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" spread="35.0"/>
                    <measurement group_id="O2" value="50.5" spread="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1" spread="49.7"/>
                    <measurement group_id="O2" value="74.8" spread="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" spread="47.2"/>
                    <measurement group_id="O2" value="65.4" spread="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" spread="42.2"/>
                    <measurement group_id="O2" value="52.3" spread="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7" spread="43.2"/>
                    <measurement group_id="O2" value="45.8" spread="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay</title>
        <time_frame>day of hospital discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitagel</title>
            <description>Vitagel [Orthovita Inc., Malvern, PA], a collagen/thrombin and autologous platelet hemostatic agent, is applied just prior to surgical closure during primary total knee arthroplasty</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No Vitagel used during primary total knee arthroplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.9"/>
                    <measurement group_id="O2" value="3.4" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score Scale</title>
        <description>A single scoring system used to evaluate overall pain on a scale of integers 0 to 10, with 0 representing &quot;no pain&quot; and 10 representing &quot;unbearable pain.&quot; Thus, in this context, lower values represent better outcomes.</description>
        <time_frame>within 30 days before surgery (preop), 4 weeks after surgery, 12 weeks after surgery</time_frame>
        <population>Vitagel (n=49 at preoperative, 4 wk, 12 wk); Control (n=50 at preoperative, 4 wk; n=49 at 12 wk since one control subject was lost to follow-up)</population>
        <group_list>
          <group group_id="O1">
            <title>Vitagel</title>
            <description>Vitagel [Orthovita Inc., Malvern, PA], a collagen/thrombin and autologous platelet hemostatic agent, is applied just prior to surgical closure during primary total knee arthroplasty</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No Vitagel used during primary total knee arthroplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score Scale</title>
          <description>A single scoring system used to evaluate overall pain on a scale of integers 0 to 10, with 0 representing &quot;no pain&quot; and 10 representing &quot;unbearable pain.&quot; Thus, in this context, lower values represent better outcomes.</description>
          <population>Vitagel (n=49 at preoperative, 4 wk, 12 wk); Control (n=50 at preoperative, 4 wk; n=49 at 12 wk since one control subject was lost to follow-up)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Preoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="2.5"/>
                    <measurement group_id="O2" value="6.0" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks Postoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="2.1"/>
                    <measurement group_id="O2" value="2.5" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks Postoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="2.2"/>
                    <measurement group_id="O2" value="1.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Knee Injury and Osteoarthritis Outcome Score (KOOS)</title>
        <description>A scoring system used to evaluate the patient's opinion about his/her knee and associated problems. Subscales include 1) pain, 2) other symptoms, 3) function in daily living (ADL), 4) function in sport and recreation (Sport/Rec), and 5) knee related quality of life (QOL). Standardized answer options are given (5 Likert boxes) and each question is assigned a score from 0 to 4. A normalized score between 0 to 100 is calculated for each subscale. Subscale scores are generally not combined; rather, they are reported separated. Higher values represent better outcomes (i.e., less extreme symptoms).</description>
        <time_frame>within 30 days before surgery (preop), 4 weeks after surgery, 12 weeks after surgery</time_frame>
        <population>Vitagel (n=49 at preoperative, 4 wk, 12 wk); Control (n=50 at preoperative, 4 wk; n=49 at 12 wk since one control subject was lost to follow-up)</population>
        <group_list>
          <group group_id="O1">
            <title>Vitagel</title>
            <description>Vitagel [Orthovita Inc., Malvern, PA], a collagen/thrombin and autologous platelet hemostatic agent, is applied just prior to surgical closure during primary total knee arthroplasty</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No Vitagel used during primary total knee arthroplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Knee Injury and Osteoarthritis Outcome Score (KOOS)</title>
          <description>A scoring system used to evaluate the patient's opinion about his/her knee and associated problems. Subscales include 1) pain, 2) other symptoms, 3) function in daily living (ADL), 4) function in sport and recreation (Sport/Rec), and 5) knee related quality of life (QOL). Standardized answer options are given (5 Likert boxes) and each question is assigned a score from 0 to 4. A normalized score between 0 to 100 is calculated for each subscale. Subscale scores are generally not combined; rather, they are reported separated. Higher values represent better outcomes (i.e., less extreme symptoms).</description>
          <population>Vitagel (n=49 at preoperative, 4 wk, 12 wk); Control (n=50 at preoperative, 4 wk; n=49 at 12 wk since one control subject was lost to follow-up)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>KOOS Pain: Preoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.5" spread="17.0"/>
                    <measurement group_id="O2" value="39.9" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KOOS Pain: 4 Wks Postoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7" spread="20.4"/>
                    <measurement group_id="O2" value="57.1" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KOOS Pain: 12 Wks Postoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.6" spread="18.8"/>
                    <measurement group_id="O2" value="75.5" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KOOS Symptoms: Preoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1" spread="18.6"/>
                    <measurement group_id="O2" value="39.6" spread="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KOOS Symptoms: 4 Wks Postoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.9" spread="19.6"/>
                    <measurement group_id="O2" value="58.4" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KOOS Symptoms: 12 Wks Postoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.9" spread="19.2"/>
                    <measurement group_id="O2" value="68.5" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KOOS Daily Living Activities: Preoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6" spread="20.9"/>
                    <measurement group_id="O2" value="45.8" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KOOS Daily Living Activities: 4 Wks Postoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0" spread="19.5"/>
                    <measurement group_id="O2" value="67.7" spread="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KOOS Daily Living Activities: 12 Wks Postoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2" spread="16.5"/>
                    <measurement group_id="O2" value="81.2" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KOOS Sports/Recreation: Preoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" spread="22.6"/>
                    <measurement group_id="O2" value="12.2" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KOOS Sports/Recreation: 4 Wks Postoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" spread="29.2"/>
                    <measurement group_id="O2" value="28.1" spread="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KOOS Sports/Recreation: 12 Wks Postoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.0" spread="31.8"/>
                    <measurement group_id="O2" value="51.6" spread="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KOOS Quality of Life: Preoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" spread="24.3"/>
                    <measurement group_id="O2" value="27.7" spread="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KOOS Quality of Life: 4 Wks Postoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0" spread="29.0"/>
                    <measurement group_id="O2" value="51.0" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KOOS Quality of Life: 12 Wks Postoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" spread="22.6"/>
                    <measurement group_id="O2" value="12.2" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vitagel</title>
          <description>Vitagel [Orthovita Inc., Malvern, PA], a collagen/thrombin and autologous platelet hemostatic agent, is applied just prior to surgical closure during primary total knee arthroplasty</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>No Vitagel used during primary total knee arthroplasty</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wael K Barsoum, MD</name_or_title>
      <organization>The Cleveland Clinic</organization>
      <phone>216-444-7515</phone>
      <email>barsouw@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

